Mass spectrometry use in chronic kidney disease study
Link between cardiovascular mortality and chronic kidney disease has been studied.

HPLC, UHPLC

Mass spectrometry use in chronic kidney disease study

17 May, 2011

Published over 15 years ago. See the latest and most current information on HPLC, UHPLC.

Mass spectrometry has been used to study the increase of cardiovascular mortality among patients with chronic kidney disease (CKD).

The study, published by Proteome Science, stated that although a link between atherosclerosis, which is a major cause of cardiovascular mortality, and kidney dysfunction is undeniable, the factors enhancing CKD-mediated plaque formation are not fully understood.

To increase the awareness of formation, a team of scientists including Magdalena Luczak, Dorota Formanowicz, Elzbieta Pawliczak, Maria Wanic-Kossowska, Andrzej Wykretowicz and Marek Figlerowic carried out a comparative proteomic analysis of blood plasma proteins isolated from 75 patients in assorted stages of renal dysfunction (CKD group), 25 patients with advanced cardiovascular disease (CVD group) and 25 healthy volunteers (HV group).

With the use of mass spectrometry, the study revealed that there are at least two different processes that contribute to plaque formation in CKD- and CVD-mediated atherosclerosis, with a more intense inflammatory process seen in CKD patients.

However, it also suggested that there are notable differences in the effectiveness of cholesterol transport in both patient groups. 

Latest News

Explore Our Other Sites

Labmate Online
Single medium supports both 2D and 3D pluripotent stem cell culture and growth
Explore more Arrow
Envirotech Online
Peristaltic pumps for high-purity oxygen applications
Explore more Arrow
Pollution Solutions Online
Vacuum technology enables efficient lithium-ion battery recycling with recovery rates of up to 95%
Explore more Arrow
Petro Online
The expanding role of high-temperature, high-shear viscometry in modern engine oil development
Explore more Arrow